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   Which smoking cessation  
interventions work best?
EvidEncE-basEd answEr
A nicotine replacement therapy  (NRT), bupropion, nortriptyline, 
clonidine, and varenicline are all effective, 
although insufficient evidence exists to 
recommend one intervention over another 
(SOR: A, systematic reviews). 
Effective nonpharmacologic interventions 
include brief physician advice and more in-
tensive counseling, such as proactive tele-
phone counseling, group and individual 
counseling, and use of quit lines (SOR: A, 
systematic reviews).
Evidence summary
NRT. A Cochrane review of 111 randomized 
controlled trials (RCTs) with a total of >40,000 
subjects evaluated abstinence rates after 6 
months of NRT and placebo or no treatment.1 
All forms of NRT increased abstinence vs pla-
cebo or no treatment, independent of setting, 
duration of treatment, and intensity of non-
pharmacologic therapies. Overlapping confi-
dence intervals suggested that no one form of 
NRT was superior. (The TABLE summarizes all 
the studies discussed here.) 
z Bupropion. A Cochrane review of 
36 RCTs (N=11,140) showed higher absti-
nence rates with bupropion than placebo after 
≥6 months of follow-up (average quit rate 17% 
vs 9%). Duration (6 vs 12 months) and inten-
sity (150 vs 300 mg) of therapy didn’t influ-
ence the results.2 Six separate RCTs comparing 
bupropion plus NRT with NRT alone showed 
significant heterogeneity, but found no signifi-
cant differences using a mixed-effects model.2 
z Nortriptyline. A Cochrane review that 
pooled results from 6 RCTs (N=975) showed 
superior 6-month abstinence rates for nortrip-
tyline compared with placebo.2 Adding nicotine 
patches in other RCTs (N=1219) didn’t change 
abstinence rates.2 No long-term studies have ex-
amined other tricyclic antidepressants. 
z Clonidine. A pooled analysis of 6 RCTs 
found clonidine superior to placebo after 
≥12 weeks of follow-up.3 Results were heavily 
influenced by one trial limited to heavy smok-
ers and poor tolerability due to adverse effects 
of therapy, especially sedation and dry mouth.
z Nicotine receptor partial agonists and 
antagonists. Standard dose varenicline was 
more than twice as likely as placebo to produce 
abstinence at 6 months in a Cochrane review of 
10 RCTs.4 Lower doses were slightly less effec-
tive, but had fewer side effects. Adverse effects 
included mild to moderate nausea and sleep 
disorders; causation has not been established 
between varenicline and rare postmarketing 
reports of severe psychiatric disturbances.4,5 
The pooled results of 3 RCTs suggested 
that varenicline was superior to bupropion, 
but different abstinence rates for bupropion 
users in other placebo-controlled trials neces-
sitate caution in interpreting these results.4 Va-
renicline was not superior to NRT.4
One RCT (N=48) comparing nicotine 
patches plus the nicotine antagonist meca-
mylamine with patches plus placebo found im-
proved abstinence rates at 6 and 12 months; a 
larger RCT didn’t support these findings.6 
These interventions are not supported
A review of placebo-controlled RCTs found 
no evidence of improved abstinence at 6 to 
12 months with fluoxetine, paroxetine, sertra-
line, venlafaxine, citalopram, or monoamine 
oxidase inhibitors, alone or as adjuncts to NRT.2 
No good evidence supports using anxio-
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lytics, silver acetate, Nicobrevin (a nicotine- 
free smoking cessation aid), lobeline, or nal-
trexone for smoking cessation.7-9 
Simple advice and quit lines help
A Cochrane review of 17 RCTs found that 
simple advice improved quit rates and main-
tenance of abstinence at 12 months.10-13
A review of 9 RCTs (N>24,000). found that 
telephone quit lines increased abstinence, 
particularly after more than 2 sessions.14 
No high-quality studies demonstrate the 
effectiveness of acupuncture, hypnotherapy, 
or acupressure for smoking cessation.15,16
Recommendations
The Agency for Health Care Research and 
Quality recommends counseling (including 
individual, group, and telephone sessions and 
brief physician advice) in addition to sustained-
release bupropion, NRT, and varenicline as 
first-line agents. It considers clonidine and nor-
triptyline second-line therapies.17                        JFP
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NrT, nicotine replacement therapy.
*an effect size >1.0 means that patients using this intervention are more likely not to smoke at 6 to 12 months; larger 
numbers correlate with greater effectiveness.
 
Intervention
No. of 
studies
Effect size* (95% 
confidence interval)
 
Total N
NrT vs placebo or no treatment1 111 1.58 (1.50-1.66) >40,000
Bupropion vs placebo2 36 1.69 (1.53-1.85) 11,140
Bupropion 300 mg/d vs 150 mg/d2 3 1.08 (0.93-1.26) 2042
Bupropion + NrT vs NrT2 6 1.23 (0.67-2.26) 1106
Nortriptyline vs placebo2 6 2.03 (1.48-2.78) 975
Nortriptyline + NrT vs NrT2 4 1.29 (0.97-1.72) 1219
clonidine vs placebo3 6 1.63 (1.22-2.18) 776
Varenicline vs placebo, standard dose4
Varenicline vs placebo, low dose4
Varenicline vs bupropion4
Varenicline vs NrT4
10
4
3
2
2.31 (2.01-2.66)
2.09 (1.56-2.78) 
1.52 (1.22-1.88)
1.13 (0.94-1.35)
4443
1272
1622
778
mecamylamine + NrT vs NrT+ placebo6 1 37.5% vs 12.5% 48
Simple advice vs usual care10-13 17 1.66 (1.42-1.94) 15,930
Patient-initiated telephone quit line vs usual care14 9 1.37 (1.26-1.50) 24,000
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